Viridian Therapeutics, Inc.\DE (VRDN) Operating Income: 2014-2025
Historic Operating Income for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -$40.0 million.
- Viridian Therapeutics, Inc.\DE's Operating Income rose 52.07% to -$40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$328.1 million, marking a year-over-year decrease of 15.93%. This contributed to the annual value of -$299.0 million for FY2024, which is 17.52% down from last year.
- According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Operating Income is -$40.0 million, which was up 62.52% from -$106.8 million recorded in Q2 2025.
- In the past 5 years, Viridian Therapeutics, Inc.\DE's Operating Income registered a high of -$14.1 million during Q3 2021, and its lowest value of -$106.8 million during Q2 2025.
- Moreover, its 3-year median value for Operating Income was -$72.2 million (2024), whereas its average is -$72.2 million.
- The largest annual percentage gain for Viridian Therapeutics, Inc.\DE's Operating Income in the last 5 years was 67.90% (2021), contrasted with its biggest fall of 182.37% (2021).
- Over the past 5 years, Viridian Therapeutics, Inc.\DE's Operating Income (Quarterly) stood at -$29.1 million in 2021, then tumbled by 68.72% to -$49.1 million in 2022, then slumped by 45.68% to -$71.5 million in 2023, then decreased by 22.38% to -$87.5 million in 2024, then surged by 52.07% to -$40.0 million in 2025.
- Its Operating Income was -$40.0 million in Q3 2025, compared to -$106.8 million in Q2 2025 and -$93.9 million in Q1 2025.